Pharmaceutical Technology1m
Intellia’s gene editing therapy shows early potential in rare heart condition
Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...
Pharmaceutical Technology15m
Sandoz’s Afqlir gains EC marketing authorisation for retinal diseases
The European Commission (EC) has granted marketing authorisation for Sandoz ‘s Afqlir, a biosimilar to the reference medicine ...
Pharmaceutical Technology4h
AHA 2024: Plozasiran demonstrates promising Phase III results in FCS adults
During AHA 2024, data were presented from the Phase III trial of plozasiran targeting adults with genetically or clinically ...
Pharmaceutical Technology3h
AbbVie’s Elahere wins European approval for certain ovarian cancers
The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.
Pharmaceutical Technology3h
FDA approves Syndax’s Revuforj to treat leukaemia
The US FDA has approved Syndax Pharmaceuticals' Revuforj (revumenib) for treating acute leukaemia with KMT2A translocation.
Pharmaceutical Technology6h
EMA’s CHMP to approve BMS’ Opdivo for colorectal cancer
The EMA's CHMP has recommended approval of a combination therapy of BMS's Opdivo and Yervoy for the treatment of colorectal ...
Pharmaceutical Technology5h
AHA 2024: Lerodalciep provides promising results in open-label extension trial, LIBERATE-OLE
At AHA 2024, clinical trial results were presented from the ongoing open-label extension trial, LIBERATE-OLE, involving ...